Ubs Group Ag Liminal Bio Sciences Inc. Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.32 - $0.5 $776 - $1,213	2,426 Added 34657.14%	2,433 $0
Q3 2022 Nov 10, 2022	SELL	$0.4 - $0.59 $3,058 - $4,511	-7,647 Reduced 99.91%	7 $0
Q2 2022 Aug 10, 2022	BUY	$0.44 - $0.97 $156 - $344	355 Added 4.86%	7,654 $4,000
Q1 2022 May 16, 2022	BUY	$0.82 - $1.13 $4,697 - $6,473	5,729 Added 364.9%	7,299 $7,000
Q4 2021 Feb 14, 2022	BUY	$0.92 - $2.2 $1,437 - $3,438	1,563 Added 22328.57%	1,570 $2,000
Q3 2021 Nov 15, 2021	SELL	$2.15 - $3.92 $12,093 - $22,050	-5,625 Reduced 99.88%	7 $0
Q2 2021 Aug 13, 2021	BUY	$3.75 - $5.17 $21,093 - $29,081	5,625 Added 80357.14%	5,632 $22,000
Q1 2021 May 12, 2021	SELL	$3.94 - $6.43 $78 - $128	-20 Reduced 74.07%	7 $0
Q4 2020 Feb 11, 2021	SELL	$3.68 - $11.02 $2,859 - $8,562	-777 Reduced 96.64%	27 $0
Q3 2020 Nov 12, 2020	BUY	$10.51 - $23.79 $8,334 - $18,865	793 Added 7209.09%	804 $9,000
Q2 2020 Jul 31, 2020	SELL	$6.3 - $11.35 $9,298 - $16,752	-1,476 Reduced 99.26%	11 $0
Q1 2020 May 01, 2020	BUY	$5.4 - $12.93 $1,695 - $4,060	314 Added 26.77%	1,487 $10,000
Q4 2019 Feb 14, 2020	BUY	$5.47 - $11.33 $6,416 - $13,290	1,173 New	1,173 $10,000

234

Ticker LMNL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,042,600
Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the trea...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.